This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Sbi Biotech Co., Ltd.. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Takumi Hosozawa: Innovator in Immune-Mediated Disorder Treatments
Introduction
Takumi Hosozawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic solutions for immune-mediated disorders. His innovative work has the potential to impact the treatment landscape for various inflammatory diseases.
Latest Patents
Takumi Hosozawa holds a patent for "TLR inhibitory oligonucleotides and their use." This patent describes inhibitory oligonucleotides with partial phosphorothioation that exhibit reduced toxicity while effectively blocking NF-kB activation induced by TLR9 and TLR7/8 agonists. The oligonucleotides inhibit the production of proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFa). Furthermore, they prevent interferon (IFN) production from human PBMC induced by TLR9 agonists. These oligonucleotides have potential applications as remedies for treating immune-mediated disorders, including rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes, and inflammatory cytokine-mediated diseases.
Career Highlights
Takumi Hosozawa's career is marked by his dedication to advancing biotechnological innovations. His work at Sbi Biotech Co., Ltd. has positioned him as a key figure in the development of novel therapeutic strategies. His research focuses on harnessing the power of oligonucleotides to modulate immune responses effectively.
Collaborations
Takumi has collaborated with notable colleagues, including Eiji Esashi and Koji Ishida. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in biotechnology.
Conclusion
Takumi Hosozawa's contributions to the field of biotechnology, particularly through his patent on TLR inhibitory oligonucleotides, showcase his commitment to addressing immune-mediated disorders. His work has the potential to lead to significant advancements in therapeutic options for patients suffering from various inflammatory diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile